Open AccessThis article is
- freely available
Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation
Comprehensive Transplant Center Feinberg School of Medicine, Northwestern University, 303 E Chicago Ave., Tarry Building Suite 11-703, Chicago, IL 60611-3008, USA
* Author to whom correspondence should be addressed.
Received: 23 March 2012; in revised form: 30 April 2012 / Accepted: 7 May 2012 / Published: 10 May 2012
Abstract: Immunologic risk in kidney transplantation is typically minimized by avoiding, or at least limiting, the potential of donor specific humoral responses by testing for the presence of donor-specific antibodies (DSA). Additionally, selecting donor and recipient pairs with the least number of human leukocyte antigen (HLA) mismatches has been shown to play a role in transplant outcome. However, numerous other factors may play a role in the success of transplant outcome and patient health. Specifically, the use of T-cell allospecific ELISPOT assays have helped elucidate the role of pre-formed cellular responses as additional factors in post-transplant outcome. In this review, we will evaluate numerous uses of ELISPOT assays to assess the pre- and post-transplant immunologic risk of rejection episodes, graft survival and even viral susceptibility as well as the utility of ELISPOT assays in monitoring tolerance and withdrawal of immunosuppressive medications following kidney transplantation.
Keywords: ELISPOT; kidney; transplant; risk assessment
Citations to this Article
Cite This Article
MDPI and ACS Style
Zitzner, J.R.; Tambur, A.R. Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation. Cells 2012, 1, 100-110.
Zitzner JR, Tambur AR. Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation. Cells. 2012; 1(2):100-110.
Zitzner, Jennifer R.; Tambur, Anat R. 2012. "Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation." Cells 1, no. 2: 100-110.